SCHEMBL5012986

SCHEMBL5012986

CCCC1CC(=O)N(C(CCC)C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.43
BRD4 O60885 3/20 0.38
MAPT P10636 1/20 0.38
MDM2 Q00987 1/20 0.37
MME P08473 1/20 0.35
FYN P06241 1/20 0.33
SLC6A3 Q01959 3/20 0.33
SLC6A2 P23975 2/20 0.33
CHRM1 P11229 1/20 0.32
AKR1A1 P14550 1/20 0.32
CHRM3 P20309 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
ADRA1A P35348 1/20 0.32
HRH1 P35367 1/20 0.32
DRD3 P35462 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2329044 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL22231243 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL2322722 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL2322732 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL16223981 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL31030093 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL31030092 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL22426199 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL22129282 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME
SCHEMBL6869302 0.91 BRD4 (0.38) ACEBRD4MAPTMDM2MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7358276-B2 for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent UCB, S.A. (BE) 2008-04-15 US disclosed
US-20050171188-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171188-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 ACE 1587/4885BRD4 2140/4885MAPT 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.